Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Mar 23;7:369. doi: 10.1038/s41598-017-00473-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

AT2R and Mas antagonist attenuated the AngII-enhanced anticoagulant effects of rivaroxaban. Mice were administered with rivaroxaban (RivX, 5 mg/kg body weight/day) or AngII (1,500 ng/kg/min) in the presence of AT1R antagonist olmesartan medoxomil (OM, 0.5 mg/kg/day), or AT2R antagonist PD123319 (3 mg/kg/day), or Mas antagonist A-779 (2 mg/kg/day) for 2 weeks. (a) Under isoflurane anesthesis, bleeding time was assessed. Blood was collected by cardiac puncture to determine the plasma levels of thrombin-antithrombin (TAT) complex (b) and TF pathway inhibitor (TFPI) (c), as well as the plasma activities of TFPI (d). The bars show the mean ± SEM (n = 5–6). ^* P < 0.05 compared with the parallel RivX and AngII co-treated group.